- Home
- GLUE
as 11-21-2024 3:35pm EST
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 475.5M | IPO Year: | 2021 |
| Target Price: | $14.67 | AVG Volume (30 days): | 6.1M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.91 - $12.40 | Next Earning Date: | 11-07-2024 |
| Revenue: | $14,975,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -73.79% |
Stock Insider Trading Activity of Monte Rosa Therapeutics Inc. (GLUE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | GLUE | 10% Owner | Sep 20 '24 | Sell | $6.53 | 1,132,566 | $7,395,202.95 | 5,099,336 |
Latest Monte Rosa Therapeutics Inc. News
GLUE Breaking Stock News: Dive into GLUE Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet
GlobeNewswire
8 days ago
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Simply Wall St.
10 days ago
Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),
Zacks
14 days ago
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
14 days ago
Monte Rosa Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
14 days ago
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Zacks
15 days ago
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice
Zacks
22 days ago
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade
Compare GLUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLUE Monte Rosa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.